
    
      This study is designed to explore the effeicency and toxicities of rituximab combined with
      chidamide and lenalidomide in patients with relapsed or refractory AITL. The primary end
      point is PFS, and second end point is OS, ORR and toxicities according to CTCAE 5.0.
    
  